Related Experiment Video

Updated: Jun 10, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

[CD47 and leukemia stem cells]

Qian-Song Cheng1, Xing-Bing Wang

  • 1Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|August 21, 2010
PubMed

Insights

CD47 protein, also known as integrin-associated protein (IAP), inhibits macrophage phagocytosis. High CD47 expression on leukemia stem cells (LSCs) in AML patients hinders immune clearance, impacting prognosis and targeted therapy.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • CD47, an immunoglobulin-like protein, binds to SIRPα on macrophages, inhibiting phagocytosis.
  • Normal hematopoietic stem cells (HSCs) express CD47 for stability.
  • Leukemia stem cells (LSCs) in AML patients exhibit high CD47 expression, evading immune clearance.

Purpose of the Study:

  • To review the expression and function of CD47 on HSCs and LSCs.
  • To explore the role of CD47 in Acute Myeloid Leukemia (AML) prognosis.
  • To discuss CD47 as a target for AML therapy.

Main Methods:

  • Literature review of studies on CD47 expression and function in AML.
  • Analysis of CD47's role in immune evasion by LSCs.
  • Examination of CD47-targeting strategies in AML treatment.

Main Results:

  • CD47 acts as a 'don't eat me' signal, protecting LSCs from macrophage phagocytosis.
  • High CD47 expression correlates with poor prognosis in AML.
  • Targeting CD47 may restore macrophage-mediated clearance of LSCs.

Conclusions:

  • CD47 is a critical regulator of immune evasion in AML.
  • Modulating CD47 presents a promising therapeutic avenue for AML treatment.
  • Further research into CD47-based therapies is warranted for improved AML outcomes.

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...